Valuation: Vivesto AB

Market Cap 80.27M 7.87M 7.17M 6.64M 6.01M 11.27M 735M 11.79M 31.84M 397M 29.54M 28.92M 1.26B P/E 2026 *
-2.59x
P/E 2027 * -2.06x
Enterprise Value 69.27M 6.79M 6.19M 5.73M 5.18M 9.72M 635M 10.18M 27.48M 343M 25.49M 24.96M 1.09B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
52.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Vivesto AB

Manager TitleAgeSince
Chief Executive Officer 68 23/01/2023
Director of Finance/CFO 55 01/07/2026
Chief Tech/Sci/R&D Officer 39 01/01/2023
Director TitleAgeSince
Chairman 46 25/05/2022
Director/Board Member 61 26/09/2019
Director/Board Member 43 25/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-99.00% - - 7.87M
-2.29%-5.34%+28.73%+128.34% 1,204B
-2.04%-5.78%+31.91%+78.34% 643B
-0.86%-3.71%+21.74%+105.02% 501B
-0.61%-1.88%+27.36%+67.45% 378B
-3.61%-9.62%+39.73%+30.53% 327B
+0.30%-4.82%+27.07%+51.40% 285B
+1.03%-3.91%-1.57%+32.95% 270B
-1.14%-6.05%+28.16%+65.35% 237B
-1.45%-0.85%+30.03%+120.72% 207B
Average -1.07%-4.40%+25.91%+75.57% 450B
Weighted average by Cap. -1.51%-4.71%+27.02%+88.09%

Financials

2026 *2027 *
Net sales - -
Net income -28M -2.75M -2.5M -2.32M -2.1M -3.93M -257M -4.11M -11.11M -139M -10.3M -10.09M -439M -39M -3.83M -3.49M -3.23M -2.92M -5.47M -357M -5.73M -15.47M -193M -14.35M -14.05M -612M
Net Debt -11M -1.08M -983K -910K -823K -1.54M -101M -1.62M -4.36M -54.45M -4.05M -3.96M -172M -20M -1.96M -1.79M -1.65M -1.5M -2.81M -183M -2.94M -7.93M -99.01M -7.36M -7.21M -314M
Logo Vivesto AB
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Employees
4